Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning

British Journal of Haematology

Volumn 129, Issue 2, 2005, Pages 229-239

  Cohen, Jonathan ^a   Gandhi, Minal ^a   Naik, Paru ^a   Cubitt, David ^a   Rao, Kanchan ^a   Thaker, Urvashi ^a   Davies, E Graham ^a   Gaspar, H Bobby ^a,b   Amrolia, Persis J ^a,b,c   Veys, Paul ^a  

^a Gt Ormond Street Hospital NHS Trust ^*  (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Epstein Barr virus; Lymphoproliferative disease; Reduced intensity conditioning; Stem cell transplant; Viraemia

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; RITUXIMAB; THYMOCYTE ANTIBODY; VALACICLOVIR;

ADOLESCENT; ARTICLE; B LYMPHOCYTE; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONVENTIONAL INTENSITY CONDITIONING; DESENSITIZATION; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREDICTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; VIREMIA; VIRUS INFECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTILYMPHOCYTE SERUM; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNIZATION, PASSIVE; INCIDENCE; INFANT; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MULTIVARIATE ANALYSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 20244382569     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05439.x     Document Type: Article

References (32)

1. Amrolia, P., Gaspar, H.B., Hassan, A., Webb, D., Jones, A., Sturt, N., Mieli-Vergani, G., Pagliuca, A., Mufti, G., Hadzic, N., Davies, G. & Veys, P. (2000) Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood, 96, 1239-1246.
2. Antin, J.H., Bierer, B.E., Smith, B.R., Ferrara, J., Guinan, E.G., Sieff, C, Golan, D.E., Macklis, R.M., Tarbell, N.J. & Lynch, E. (1991) Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood, 78, 2139-2149.
3. Bhatia, S., Ramsay, N.K., Steinbuch, M., Dusenbery, K.E., Shapiro, R.S., Weisdorf, D.J., Robison, L.L., Miller, J.S. & Neglia, J.P. (1996) Malignant neoplasms following bone marrow transplantation. Blood, 87, 3633-3639.
4. Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O'Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. & Milligan, D.W. (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99, 4357-4363.
5. Chakrabarti, S., Milligan, D.W., Pillay, D., Mackinnon, S., Holder, K., Kaur, N., McDonald, D., Fegan, C.D., Waldmann, H., Hale, G., Rickinson, A. & Steven, N. (2003) Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood, 102, 839-842.
6. Curtis, R.E., Travis, L.B., Rowlings, P.A., Socie, G., Kingma, D.W., Banks, P.M., Jaffe, E.S., Sale, G.E., Horowitz, M.M., Witherspoon, R.P., Shriner, D.A., Weisdorf, D.J., Kolb, H.J., Sullivan, K.M., Sobocinski, K.A., Gale, R.P., Hoover, R.N., Fraumeni, J.F. Jr & Deeg, H.J. (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood, 94, 2208-2216.
7. van Esser, J.W., van der Holtm, B., Meijer, E., Niesters, H.G., Trenschel, R., Thijsen, S.F., van Loon, A.M., Frassoni, F., Bacigalupo, A., Schaefer, U.W., Osterhaus, A.D., Gratama, J.W., Lowenberg, B., Verdonck, L.F. & Cornelissen, J.J. (2001a) Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood, 98, 972-978.
8. van Esser, J.W., Niesters, H.G., Thijsen, S.F., Meijer, E., Osterhaus, A.D., Wolthers, K.C., Boucher, C.A., Gratama, J.W., Budel, L.M., van der Holt, B., van Loon, A.M., Lowenberg, B., Verdonck, L.F. St Cornelissen, J.J. (2001b) Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. British Journal of Haematology, 113, 814-821.
9. van Esser, J.W.J., Niesters, H.G.M., van der Holt, B., Meijer, E., Osterhaus, A.D.M.E., Gratama, J.W., Verdonck, L.F., Lowenberg, B. & Cornelissen, J.J. (2002) Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood, 99, 4364-4369.
10. Faye, A., Quartier, P., Reguerre, Y., Lutz, P., Garret, A.S., Dehee, A., Rohrlich, P., Peuchmaur, M., Matthieu-Boue, A., Fischer, A. & Vilmer, E. (2001) Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. British Journal of Haematology, 115, 112-118.
11. Gross, T.G., Steinbuch, M., DeFor, T., Shapiro, R.S., McGlave, P., Ramsay, N.K., Wagner, J.E. & Filipovich, A.H. (1999) B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplantation, 23, 251-258.
12. Hale, G. & Waldmann, H. (1998) Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH users. Blood, 91, 3079-3083.
13. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835-3849.
14. Ho, A.Y., Adams, S., Shaikh, H., Pagliuca, A., Devereux, S. & Mufti, G.J. (2002) Fatal donor-derived Epstein-Barr virus-associated posttransplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplantation, 29, 867-869.
15. Hoshino, Y., Kimura, H., Tanaka, N., Tsuge, I., Kudo, K., Horibe, K., Kato, K., Matsuyama, T., Kikuta, A., Kojima, S. & Morishima, T. (2001) Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. British Journal of Haematology, 115, 105-111.
16. Jabs, W.J., Hennig, H., Kittel, M., Pethig, K., Smets, F., Bucsky, P., Kirchner, H. & Wagner, H.J. (2001) Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. Journal of Clinical Microbiology, 39, 564-569.
17. Lankester, A.C., van Tol, M.J., Vossen, J.M., Kroes, A.C. & Claas, E. (2002) Epstein-Barr virus (EBV)-DNA quantification in paediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease. Blood, 99, 2630-2631.
18. Lucas, K.G., Burton, R.L., Zimmerman, S.E., Wang, J.H., Cornetta, K.G., Robertson, K.A., Lee, C.H. & Emanuel, D.J. (1998) Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood, 91, 3654-3661.
19. Meij, P., van Esser, J.W., Niesters, H.G., van Baarle, D., Miedema, F., Blake, N., Rickinson, A.B., Leiner, I., Pamer, E., Lowenberg, B., Cornelissen, J.J. & Gratama, J.W. (2003) Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood, 101, 4290-4297.
20. Meijer, E., Slaper-Cortenbach, I.C., Thijsen, S.F., Dekker, A.W. & Verdonck, L.F. (2002) Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique. Bone Marrow Transplantation, 29, 335-339.
21. Micallef, I.N.M., Chhanabhai, M., Gascoyne, R.D., Shepherd, J.D., Fung, H.C., Nantel, S.H., Toze, C.L., Klingemann, H.G., Sutherland, H.J., Hogge, D.E., Nevill, T.J., Le, A. & Barnett, M.J. (1998) Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplantation, 22, 981-987.
22. Milpied, N., Coste-Burel, M., Accard, F., Moreau, A., Moreau, P., Garand, R. & Harousseau, J.L. (1999) Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplantation, 23, 629-630.
23. Milpied, N., Vasseur, B., Parquet, N., Garnier, J.L., Antoine, C., Quartier, P., Garret, A.S., Bouscary, D., Faye, A., Bourbigot, B., Reguerre, Y., Stoppa, A.M., Bourquard, P., de Ligny, B.H., Dubief, F., Mathieu-Boue, A. & Leblond, V. (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Annals of Oncology, 11, 113-116.
24. Nalesnik, M.A. (1998) Clinical and pathological features of posttransplant lymphoproliferative disorders (PTLD). Springer Seminars in Immunopathology, 20, 325-342.
25. Peggs, K.S., Banerjee, L., Thomson, K. & Mackinnon, S. (2003) Post transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion. Bone Marrow Transplantation, 31, 725-726.
26. Rao, K., Amrolia, P.J., Jones, A., Cale, C.M., Naik, P., King, D., Davies, G.E., Caspar, H.B. & Veys, P.A. (2005) Improved survival after unrelated donor bone marrow transplant in children with primary immunodeficiency using a reduced intensity conditioning regimen. Blood, 105, 879-885.
27. Rooney, C.M., Loftin, S.K., Holladay, M.S., Brenner, M.K., Krance, R.A. & Heslop, H.E. (1995) Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. British Journal of Haematology, 89, 98-103.
28. Rooney, C.M., Smith, C.A., Ng, C.Y.C., Loftin, S.K., Sixbey, J.W., Can, Y.J., Srivastava, D.K., Bowman, L.C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549-1555.
29. Shroff, R., Trompeter, R., Cubitt, D., Thaker, U. & Rees, L. (2002) Epstein-Barr virus monitoring in paediatric renal transplant recipients. Paediatric Nephrology, 17, 770-775.
30. Sirvent-von Bueltzingsloewen, A., Morand, P., Buisson, M., Souillet, G., Chambost, H., Bosson, J.L. & Bordigoni, P. (2002) A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplantation, 29, 21-28.
31. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben Tal, O., Eldor, A. & Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756-763.
32. Wagner, H.J., Cheng, Y.C., Huls, M.H., Gee, A.P., Kuehnle, L, Krance, R.A., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2004) Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood, 103, 3979-3981.